Partial Enteral Nutrition With a Unique Diet vs. Exclusive Enteral Nutrition for the Treatment of Pediatric Crohn's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

74 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-01-31

Study Completion Date

2018-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the efficacy and tolerability of a novel dietary intervention for early CD based on partial enteral nutrition, and to compare it to the gold standard but difficult to implement dietary intervention- Exclusive enteral nutrition with Modulen .

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cyclic Exclusive Enteral Nutrition as Maintenance Therapy for Pediatric Crohn's Disease

NCT02201693

Crohn's Disease

COMPLETED NA

Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis

NCT00265772

Crohn's Disease Pediatric

UNKNOWN PHASE4

Diet for Induction and Maintenance of Remission and Re-biosis in Crohn's Disease

NCT02843100

Crohn's Disease

COMPLETED NA

The Crohn's Disease Exclusion Diet With Partial Enteral Nutrition or Alone in Adult Patients With Crohn's Disease

NCT02231814

Crohn's Disease

COMPLETED NA

CD-TREAT Diet: a Novel Therapy for Active Luminal Crohn's Disease

NCT03171246

Crohn Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background: Crohn's disease is clearly on the rise in countries exposed to industrialization and western diet. Several factors may implicate diet in the pathogenesis of CD or in disease activity. The strongest argument for an effect of diet is the effect of exclusive enteral nutrition (EEN) on disease activity in CD. 40-80% of children , fed an exclusive liquid diet, irrespective of which diet, will enter complete remission, often with normalization of inflammatory markers. The effect of formula has been shown to be independent of fat or protein composition in pediatric studies, but to be dependent on exclusion of normal diet.Thus, rather than the composition of EEN being associated with remission of disease it may be the exclusion of certain components of the Western diet may be responsible for improvement.

Methods:This is a prospective randomized controlled trial, in patients with a recent diagnosis of CD (up to two years),aged 4-18, comparing two arms over 12 weeks of therapy.

Group 1:will receive 50% of their dietary needs from a polymeric formula ( Modulen, Nestle) and a limited whole food diet for 6 weeks/ Group 2: will receive EEN with Modulen for 6 weeks. At the end of 6 weeks, all patients entering remission (irrespective of randomization) will enter the second 6 week phase, continuing 25 % of calories as Modulen in both groups. Patients in remission from group 2 will continue to consume 25% of calories as Modulen and be allowed free diet , patients in Group 1 will continue 25% of calories from Modulen but continue restricted diet.

Patients will be seen at onset (week 0), weeks 3 and 6, 12 and 24 weeks.

We hypothesize that by withdrawing the offending dietary agents we can achieve an equal remission rate with improved tolerability. This study will evaluate response, remission and tolerability in both groups, as well as the effects of nutrition on bone health.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Unique Diet+Partial Enteral Nutrition

Unique Diet+Partial Enteral Nutrition (PEN): This group will receive as follows:

Weeks 1-6: 50% of dietary needs from PEN (Modulen, Nestle) and 50% from a limited whole food diet.

Weeks 7-12: 25% of dietary needs from PEN (Modulen, Nestle) and 75% from a limited whole food diet.

Group Type EXPERIMENTAL

Unique Diet+Partial Enteral Nutrition

Intervention Type OTHER

Modulen - liquid dietary formula

Exclusive Enteral Nutrition (Modulen)

Exclusive Enteral Nutrition(EEN): This group will receive as follows:

Weeks 1-6: EEN(100% of dietary needs from Modulen) Weeks 7-12: 25% of dietary needs from Modulen and 75% from a free diet.

Group Type ACTIVE_COMPARATOR

Exclusive Enteral Nutrition (Modulen)

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Unique Diet+Partial Enteral Nutrition

Modulen - liquid dietary formula

Intervention Type OTHER

Exclusive Enteral Nutrition (Modulen)

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Modulen, Nestle Modulen, Nestle

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Children 4-18 years of age.
2. Patients with a diagnosis of CD-duration of disease up to 36 months
3. Have macroscopic small bowel involvement, or isolated large bowel disease confined to the right or transverse colon
4. Patients with a pediatric activity index -PCDAI ≥ 10
5. Patients will not be excluded if they have received 5ASA or an immunomodulator for \>8 weeks and the dose is stable , or if they start a thiopurine concurrently , as thiopurines are not considered sufficient to induce remission in active disease before 8 weeks as an isolated therapy.
6. Informed Consent

Exclusion Criteria

1. Patients with no disease activity ( PCDAI \<10) or severe disease ( PCDAI ≥ 40).
2. Patients who have received corticosteroids of any kind in the previous 4 weeks.
3. Patients who have started an immunomodulator in the previous 8 weeks
4. Any current biological treatment
5. Isolated Large bowel disease ( L2) involving the recto-sigmoid or descending colon
6. Patients with penetrating disease (abscess or fistula)
7. Active Perianal disease
8. Fixed stricture or small bowel obstruction
9. Normal CRP and ESR
10. Active joint disease.
11. Patients who have undergone an intestinal resection.
12. Sclerosing Cholangitis
13. Pregnancy

Minimum Eligible Age

4 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No